Somatostatin analogs as glucagon suppressants in diabetes

V. Schusdziarra, J. Rivier, R. Dobbs, M. Brown, W. Vale, Roger H Unger

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Somatostatin, an inhibitor of glucagon secretion, has been tested experimentally to evaluate its therapeutic potential in the treatment of juvenile onset diabetics (Meissner, Thum, Beischer, Winkler, Schroder, and Pfeiffer 1975; Gerich, Lorenzi, Schneider, Karam, Rivier, Guillemin and Forsham 1974). However, the potential therapeutic value of somatostatin is limited by the fact that it is relatively ineffective when injected subcutaneously and must be given by continuous intravenous infusion. The present study was designed to identify analogs that might be more effective than somatostatin upon subcutaneous adminstration. The three analogs selected for the study were [D-Trp 8]-SS, [D-Trp 8-D-Cys 14]-SS and [D-Cys 14]-SS. The study reveals that two analogs, [D-Trp 8]-SS and [D-Trp 8-D-Cys 14]-SS, have a more prolonged action in inhibiting glucagon secretion than unmodified somatostatin when injected subcutaneously, indicating that they might prove to be more useful therapeutically than somatostatin in controlling the hyperglycemia of human diabetics. No overt clinical evidence of untoward side effects, such as steatorrhea or weight loss, was observed in any dog during and after the three days of treatment with either analog as might be expected considering the inhibitory actions of unmodified somatostatin upon gastrointestinal functions. The data obtained in this study suggest that these analogs may have potential therapeutic usefulness in human juvenile-onset diabetics.

Original languageEnglish (US)
Pages (from-to)563-565
Number of pages3
JournalHormone and Metabolic Research
Volume10
Issue number6
StatePublished - 1978

Fingerprint

Medical problems
Somatostatin
Glucagon
Steatorrhea
Therapeutics
Intravenous Infusions
Hyperglycemia
Weight Loss
Dogs

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Schusdziarra, V., Rivier, J., Dobbs, R., Brown, M., Vale, W., & Unger, R. H. (1978). Somatostatin analogs as glucagon suppressants in diabetes. Hormone and Metabolic Research, 10(6), 563-565.

Somatostatin analogs as glucagon suppressants in diabetes. / Schusdziarra, V.; Rivier, J.; Dobbs, R.; Brown, M.; Vale, W.; Unger, Roger H.

In: Hormone and Metabolic Research, Vol. 10, No. 6, 1978, p. 563-565.

Research output: Contribution to journalArticle

Schusdziarra, V, Rivier, J, Dobbs, R, Brown, M, Vale, W & Unger, RH 1978, 'Somatostatin analogs as glucagon suppressants in diabetes', Hormone and Metabolic Research, vol. 10, no. 6, pp. 563-565.
Schusdziarra V, Rivier J, Dobbs R, Brown M, Vale W, Unger RH. Somatostatin analogs as glucagon suppressants in diabetes. Hormone and Metabolic Research. 1978;10(6):563-565.
Schusdziarra, V. ; Rivier, J. ; Dobbs, R. ; Brown, M. ; Vale, W. ; Unger, Roger H. / Somatostatin analogs as glucagon suppressants in diabetes. In: Hormone and Metabolic Research. 1978 ; Vol. 10, No. 6. pp. 563-565.
@article{b0c9e114cc5847839bf808124e853acb,
title = "Somatostatin analogs as glucagon suppressants in diabetes",
abstract = "Somatostatin, an inhibitor of glucagon secretion, has been tested experimentally to evaluate its therapeutic potential in the treatment of juvenile onset diabetics (Meissner, Thum, Beischer, Winkler, Schroder, and Pfeiffer 1975; Gerich, Lorenzi, Schneider, Karam, Rivier, Guillemin and Forsham 1974). However, the potential therapeutic value of somatostatin is limited by the fact that it is relatively ineffective when injected subcutaneously and must be given by continuous intravenous infusion. The present study was designed to identify analogs that might be more effective than somatostatin upon subcutaneous adminstration. The three analogs selected for the study were [D-Trp 8]-SS, [D-Trp 8-D-Cys 14]-SS and [D-Cys 14]-SS. The study reveals that two analogs, [D-Trp 8]-SS and [D-Trp 8-D-Cys 14]-SS, have a more prolonged action in inhibiting glucagon secretion than unmodified somatostatin when injected subcutaneously, indicating that they might prove to be more useful therapeutically than somatostatin in controlling the hyperglycemia of human diabetics. No overt clinical evidence of untoward side effects, such as steatorrhea or weight loss, was observed in any dog during and after the three days of treatment with either analog as might be expected considering the inhibitory actions of unmodified somatostatin upon gastrointestinal functions. The data obtained in this study suggest that these analogs may have potential therapeutic usefulness in human juvenile-onset diabetics.",
author = "V. Schusdziarra and J. Rivier and R. Dobbs and M. Brown and W. Vale and Unger, {Roger H}",
year = "1978",
language = "English (US)",
volume = "10",
pages = "563--565",
journal = "Hormone and Metabolic Research",
issn = "0018-5043",
publisher = "Georg Thieme Verlag",
number = "6",

}

TY - JOUR

T1 - Somatostatin analogs as glucagon suppressants in diabetes

AU - Schusdziarra, V.

AU - Rivier, J.

AU - Dobbs, R.

AU - Brown, M.

AU - Vale, W.

AU - Unger, Roger H

PY - 1978

Y1 - 1978

N2 - Somatostatin, an inhibitor of glucagon secretion, has been tested experimentally to evaluate its therapeutic potential in the treatment of juvenile onset diabetics (Meissner, Thum, Beischer, Winkler, Schroder, and Pfeiffer 1975; Gerich, Lorenzi, Schneider, Karam, Rivier, Guillemin and Forsham 1974). However, the potential therapeutic value of somatostatin is limited by the fact that it is relatively ineffective when injected subcutaneously and must be given by continuous intravenous infusion. The present study was designed to identify analogs that might be more effective than somatostatin upon subcutaneous adminstration. The three analogs selected for the study were [D-Trp 8]-SS, [D-Trp 8-D-Cys 14]-SS and [D-Cys 14]-SS. The study reveals that two analogs, [D-Trp 8]-SS and [D-Trp 8-D-Cys 14]-SS, have a more prolonged action in inhibiting glucagon secretion than unmodified somatostatin when injected subcutaneously, indicating that they might prove to be more useful therapeutically than somatostatin in controlling the hyperglycemia of human diabetics. No overt clinical evidence of untoward side effects, such as steatorrhea or weight loss, was observed in any dog during and after the three days of treatment with either analog as might be expected considering the inhibitory actions of unmodified somatostatin upon gastrointestinal functions. The data obtained in this study suggest that these analogs may have potential therapeutic usefulness in human juvenile-onset diabetics.

AB - Somatostatin, an inhibitor of glucagon secretion, has been tested experimentally to evaluate its therapeutic potential in the treatment of juvenile onset diabetics (Meissner, Thum, Beischer, Winkler, Schroder, and Pfeiffer 1975; Gerich, Lorenzi, Schneider, Karam, Rivier, Guillemin and Forsham 1974). However, the potential therapeutic value of somatostatin is limited by the fact that it is relatively ineffective when injected subcutaneously and must be given by continuous intravenous infusion. The present study was designed to identify analogs that might be more effective than somatostatin upon subcutaneous adminstration. The three analogs selected for the study were [D-Trp 8]-SS, [D-Trp 8-D-Cys 14]-SS and [D-Cys 14]-SS. The study reveals that two analogs, [D-Trp 8]-SS and [D-Trp 8-D-Cys 14]-SS, have a more prolonged action in inhibiting glucagon secretion than unmodified somatostatin when injected subcutaneously, indicating that they might prove to be more useful therapeutically than somatostatin in controlling the hyperglycemia of human diabetics. No overt clinical evidence of untoward side effects, such as steatorrhea or weight loss, was observed in any dog during and after the three days of treatment with either analog as might be expected considering the inhibitory actions of unmodified somatostatin upon gastrointestinal functions. The data obtained in this study suggest that these analogs may have potential therapeutic usefulness in human juvenile-onset diabetics.

UR - http://www.scopus.com/inward/record.url?scp=0018218551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018218551&partnerID=8YFLogxK

M3 - Article

VL - 10

SP - 563

EP - 565

JO - Hormone and Metabolic Research

JF - Hormone and Metabolic Research

SN - 0018-5043

IS - 6

ER -